Bobcat Bio
PrivateLast Round
Series A
Extension
Feb 25, 2025
Est. Valuation
$49.8M
Total Funding Raised
$87.49M
Company Overview
Bobcat Bio operates in Healthcare & Life Sciences and is based in Hummelstown, Pennsylvania. Its latest recorded funding round was a Series A Extension round in February 2025.
Bobcat Bio is a biotechnology company that develops autologous macrophage cell therapies for the treatment of solid tumors and hematological malignancies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Bobcat Bio Comparables
Compare Bobcat Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Avstera Therapeutics | 83% | |
| Inceptor Bio | 82% | |
| Carisma Therapeutics | 81% |
For institutional investors. Book with your work email.
Bobcat Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Feb 25, 2025 | ||||
| Grant | Aug 8, 2024 | ||||
| Series B | Jan 22, 2024 | ||||
| Grant | Sep 1, 2023 | ||||
| Series A | Sep 29, 2021 | ||||
Series A | Jul 23, 2021 |
For institutional investors. Book with your work email.
Bobcat Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| BioAdvance Capital | Series A, Series A Extension |
| Biolocity | Series B |
| Bios Partners | Series A Extension, Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 25, 2025
$7M round with BioAdvance Capital and Bios Partners
- Jan 22, 2024
$27M round led by Bios Partners and Biolocity.
For institutional investors. Book with your work email.
Bobcat Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Bobcat Bio's valuation, stock price, and market status.
Is Bobcat Bio a public or private company?
Bobcat Bio is a private company.
What is the current stock price of Bobcat Bio?
Bobcat Bio is a private company, so its shares have no public market price. Caplight tracks Bobcat Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Bobcat Bio worth (valuation)?
Bobcat Bio's valuation is estimated at $49.8M based on funding round data.
Can I buy Bobcat Bio stock?
Bobcat Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Bobcat Bio's last funding round?
Bobcat Bio's most recent funding round was Series A Extension on February 25, 2025.
Who are the main investors in Bobcat Bio?
Key investors in Bobcat Bio include Bios Partners.
Will Bobcat Bio IPO soon?
No public IPO plans have been announced for Bobcat Bio.
How can I track Bobcat Bio secondary market activity?
Caplight tracks bids, offers, and trades in Bobcat Bio's shares on secondary markets.